Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
Source link
Similar Posts
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Consensus Recommendation of "Buy" from Analysts
Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) have received a consensus rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. Nine investment analysts have rated the stock with a buy rating. The average 12-month target pric Source link
5 Canadian Stocks to Buy and Hold for the Next 5 Years
With all the volatility going on in the world, Canada remains a reasonably attractive place to invest. The great thing is that many Canadian stocks give you access to the broader world. If you are looking to build a diversified portfolio of quality Canadian stocks, here are five for the coming five years. Source: Getty…
2 TSX Stocks to Buy and 1 to Sell
In every market environment, there are always stocks investors are going to consider buying opportunities and ones they’d rather get rid of. The nature of markets is one that requires picking and choosing winners, and that’s what makes the game exciting. The good news for Canadian investors is that the TSX is chock full of…
The Falling $
Source : Wall Street Journal Source link
